NEW YORK (GenomeWeb News) – KineMed has licensed GeneGo’s MetaCore software for an ongoing Phase II prognostic study of chronic lymphocytic leukemia, GeneGo said today.
 
KineMed is testing a biomarker of CLL flux as a predictor of disease course that is intended to stratify indolent versus aggressive disease.
 
MetaCore is GeneGo’s flagship product and is used for target selection and validation, identification of biomarkers for disease states, and toxicology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.